- CA$6.83bn
- CA$7.95bn
- CA$5.65bn
- 94
- 91
- 37
- 86
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 3,931 | 2,292 | 4,321 | 6,118 | 5,653 |
Cost of Revenue | |||||
Gross Profit | 1,463 | 469 | 1,745 | 2,597 | 1,962 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 3,911 | 2,546 | 3,735 | 4,596 | 4,769 |
Operating Profit | 20 | -254 | 586 | 1,522 | 884 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -91 | -477 | 366 | 1,222 | 723 |
Provision for Income Taxes | |||||
Net Income After Taxes | -62 | -357 | 283 | 902 | 569 |
Net Income Before Extraordinary Items | |||||
Net Income | -62 | -357 | 283 | 902 | 569 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -62 | -357 | 283 | 902 | 569 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.086 | -1.03 | 0.997 | 3.01 | 2.14 |